China Cell Reprogramming Market Size & Outlook, 2025-2030

The cell reprogramming market in China is expected to reach a projected revenue of US$ 39.3 million by 2030. A compound annual growth rate of 11.3% is expected of China cell reprogramming market from 2025 to 2030.
Revenue, 2024 (US$M)
$21.1
Forecast, 2030 (US$M)
$39.3
CAGR, 2025 - 2030
11.3%
Report Coverage
China

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China cell reprogramming market, 2018-2030 (US$M)

China cell reprogramming market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China cell reprogramming market highlights

  • The China cell reprogramming market generated a revenue of USD 21.1 million in 2024 and is expected to reach USD 39.3 million by 2030.
  • The China market is expected to grow at a CAGR of 11% from 2025 to 2030.
  • In terms of segment, episomal reprogramming was the largest revenue generating technology in 2024.
  • MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.

Cell reprogramming market data book summary

Market revenue in 2024USD 21.1 million
Market revenue in 2030USD 39.3 million
Growth rate11% (CAGR from 2025 to 2030)
Largest segmentEpisomal reprogramming
Fastest growing segmentMRNA Reprogramming
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming
Key market players worldwideThermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies

Other key industry trends

  • In terms of revenue, China accounted for 5.2% of the global cell reprogramming market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China cell reprogramming market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 39.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell Reprogramming Market Companies

Name Profile # Employees HQ Website
Alstem View profile 11-50 Richmond, Virginia, United States, North America https://www.alstembio.com/web/
Allele Biotech View profile 11-50 San Diego, California, United States, North America http://www.allelebiotech.com/
STEMCELL Technologies View profile 501-1000 Vancouver, British Columbia, Canada, North America https://www.stemcell.com
ReproCELL View profile 51-100 Yokohama, Kanagawa, Japan, Asia http://reprocell.com
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
FUJIFILM Holdings Corp View profile 83784 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 http://www.fujifilmholdings.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

China cell reprogramming market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.


Episomal reprogramming was the largest segment with a revenue share of 32.23% in 2024. Horizon Databook has segmented the China cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.


For instance, the Chinese Academy of Sciences, Beijing Institute for Stem Cell and Regenerative Medicine, and the Institute of Zoology/Institute for Stem Cell and Regeneration announced an event, Pluripotent Stem Cell Conference (PS Conf 2023), in October 2023, building on the success of the previous PS Conf meetings in 2021 and 2022.

The discussions will focus on experiences with stem cell-derived organoids and products, accompanied by training sessions on biobanking and discussions addressing ethical and quality considerations in hPSC-derived organoids.

The Bridging Session will facilitate dialogue between Chinese and international scientific networks, fostering global collaboration on advancing stem cell standards and shaping future priorities. Such initiatives are expected to drive market growth.

Reasons to subscribe to China cell reprogramming market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China cell reprogramming market databook

  • Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into China cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China cell reprogramming market size, by technology, 2018-2030 (US$M)

China Cell Reprogramming Market Outlook Share, 2024 & 2030 (US$M)

China cell reprogramming market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online